OMass Therapeutics is developing small molecule drugs to treat diseases and immunological conditions.
OMass Therapeutics has raised €90M across 1 funding round from 6 investors, most recently a Series B round in Apr 2022. Based in Oxford, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-04-28 | Series B | €90M |
| GV,Northpond Ventures,Oxford Science Enterprises,Oxford University Innovation Fund,Sanofi Ventures,Syncona Partners |
| View deal → |
